# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Billie Holiday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML010-SYN-TD
- Date: 1948-07-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Mayfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review after a return to opioid use six days ago. **S**

## History of present illness

Ms. Holiday returns three months after starting buprenorphine. Eight days ago, on tour in another state, the pharmacy could not refill her buprenorphine because the insurer's prior authorization had lapsed. After two days without it she had withdrawal and strong cravings, and six days ago she used heroin twice. She tested the supply first and the fentanyl strip was positive; she used with her friend present and naloxone at hand, and she did not overdose. The pharmacy filled the prescription the next day, and she restarted buprenorphine that morning, after waiting until she felt withdrawal again as she had been taught; she has taken it daily since and has used no opioids for five days. She also drank more on the tour, most nights. She called the clinic as soon as she was home and wanted to be seen. She is ashamed and worried that she has lost her place in treatment. She has had no thoughts of suicide. She feels tired and low and has not been sleeping well. **S**

| Element | Detail |
|---|---|
| Return to use | Heroin twice, six days ago, after two days without buprenorphine |
| Cause of the gap | Lapsed prior authorization while on tour |
| Safety | Tested the supply (fentanyl positive); used with her friend present and naloxone at hand; no overdose |
| Buprenorphine | Restarted five days ago at 16 mg daily, without precipitated withdrawal |
| Alcohol | Drinking most nights on tour |
| Mood | Tired, low, ashamed; PHQ-9 11; item 9 scored 0 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; weight down 1.2 kg; no fever |
| Gastrointestinal | Negative | No nausea, vomiting, or diarrhea now |
| Integumentary | Negative | No injection-site redness or abscess |
| Psychiatric | Positive | Low mood, poor sleep, and shame after the return to use; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily **S**
- Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 **S**
- Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times daily **S**
- Thiamine 100 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/82 mmHg; pulse 86 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 67.4 kg; BMI 24.8 kg/m². All vital signs are synthetic.

AST: 44 U/L (high); ALT: 33 U/L; GGT: 61 U/L (high); Phosphatidylethanol (PEth): 164 ng/mL (high); PHQ-9: 11. All results are synthetic.

## Change since baseline

- AST: 52 U/L (high) at baseline, 44 U/L (high) at this visit **S**
- ALT: 38 U/L at baseline, 33 U/L at this visit **S**
- GGT: 84 U/L (high) at baseline, 61 U/L (high) at this visit **S**
- Phosphatidylethanol (PEth): 312 ng/mL (high) at baseline, 164 ng/mL (high) at this visit **S**
- PHQ-9: 9 at baseline, 11 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Tired but well; blood pressure 128/82, pulse 86 |
| Skin | No injection marks, redness, or abscess |
| Eyes | Pupils normal in size; no signs of withdrawal |
| Psychiatric | Tearful at first, then engaged in planning; no signs of intoxication |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Opioid use disorder on buprenorphine, after a brief return to use** (F11.20). A brief return to use caused by a gap in medication, not by a failure of treatment, managed safely with test strips, a companion, and naloxone. A return to use is an expected part of recovery for many people and is a reason to strengthen treatment, not to stop it. Urine test today shows buprenorphine and norfentanyl, which fits use six days ago. She keeps her place in treatment. Dr. Ortiz reviewed the plan by phone today and agrees. Safety reviewed: no thoughts of suicide or self-harm; overdose risk discussed openly. **S**
   - Continue buprenorphine with naloxone 16 mg daily.
   - Prior authorization renewed for twelve months; pharmacy chain that can fill in any state; prescription filled a week before each tour; a travel letter and the clinic number for any problem.
   - Extended-release monthly buprenorphine injection offered as a way to avoid pharmacy gaps; she would rather stay on films for now and will think about it.
   - Naloxone replaced; new test strips.
2. **Alcohol use disorder on acamprosate** (F10.20). PEth up from 96 to 164 ng/mL with heavier drinking on tour; AST 44, ALT 33, GGT 61 U/L. **S**
   - Continue acamprosate and thiamine.
   - Plan with her counselor for nights on tour: non-alcoholic drinks after shows and a call to her peer coach.
3. **Low mood after the return to use**. PHQ-9 11. On interview, the low mood, poor sleep, and shame began with the return to use and the tour; she does not describe a depressive episode, and there is no history suggesting mania. No thoughts of suicide. **S**
   - Weekly in-person counseling now that she is home.
   - PHQ-9 again at the preventive visit in six weeks.
   - The safety plan reviewed and updated with her.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Buprenorphine dose, adherence, cravings, withdrawal, and side effects | Every visit | Completed today | Gap of three days from a lapsed prior authorization, then restarted at 16 mg; no precipitated withdrawal |
| Self-management | Visit frequency | Every 1 to 2 weeks in the first month after starting, then every 2 to 4 weeks until stable | Completed today | Video check-ins every two weeks kept since the five-week visit; seen in person within days of her call |
| Laboratory | Urine drug testing, including fentanyl, explained as part of care rather than as a test of trust | At the start, then about monthly early in treatment and as needed | Completed today | Buprenorphine, norbuprenorphine, and norfentanyl, consistent with what she reported |
| Medication safety | Prescription drug monitoring program check | Before each buprenorphine prescription | Completed today | No other prescriptions |
| Medication safety | Naloxone at home and in her bag, and a trained companion | At the start; check and replace at each visit | Completed today | Not used; replaced with new test strips |
| Self-management | Overdose prevention: never using alone and fentanyl test strips | Every visit | Completed today | She tested the supply and used with a companion and naloxone; reinforced without judgment |
| Medication safety | Prescription continuity on tour (pharmacy, prior authorization, travel letter) | Before each tour | Completed today | Prior authorization renewed for twelve months; national pharmacy chain; early fill and travel letter |
| Self-management | Counseling and peer recovery support | Offered to everyone; not a condition of medication | Completed today | Weekly in-person counseling from now; peer coach |
| Survey | Drinking and PEth | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Completed today | PEth 164 ng/mL, up from 96, with heavier drinking on tour |
| Medication safety | Acamprosate adherence and kidney function | Kidney function before starting; adherence every visit | Completed today | Taking it; midday reminder working |
| Medication safety | Thiamine | While drinking heavily | Completed today | Taking thiamine daily |
| Laboratory | Liver tests (AST, ALT, GGT, albumin, bilirubin) | At intake, then every 1 to 3 months while drinking is heavy, and yearly | Completed today | AST 44, ALT 33, GGT 61 U/L |
| Laboratory | FIB-4 fibrosis score | At intake; repeat in 6 to 12 months with ongoing drinking, and every 1 to 2 years | Up to date | 1.18 at intake; repeat at six months |
| Survey | Depression screen (PHQ-9) | At intake and at each recovery visit while symptoms are present | Completed today | PHQ-9 11, item 9 scored 0; interview does not show a depressive episode |
| Survey | Mood Disorder Questionnaire | At the evaluation of a new depressive episode | Not indicated | No depressive episode on interview and no history suggesting mania |
| Survey | Suicide and overdose risk review, safety plan, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; overdose risk after the gap reviewed; the safety plan updated; the 988 Suicide & Crisis Lifeline in her phone |

## Goal progress

- Stay on buprenorphine without interruption through six months, including through any return to use. In progress; target 1948-10-19. **S**
- Naloxone at home and in her bag, and a friend trained to use it, by the one-week visit. Outcome by 1948-04-27: Two naloxone two-packs dispensed; her friend trained. **S**
- Reduce drinking to PEth below 20 ng/mL, or to the level she chooses, by six months. In progress; target 1948-10-19. **S**
- Hepatitis A and B vaccine series completed by six months. In progress; target 1948-10-19. **S**
- PHQ-9 score below 5 by six months. In progress; target 1948-10-19. **S**

## Guideline basis

- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026), Substance Abuse and Mental Health Services Administration
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019), American Association for the Study of Liver Diseases (Hepatology)
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Weekly counseling. Preventive visit in six weeks with the PHQ-9. Call the clinic the same day if a refill fails or cravings rise. **S**
- Next scheduled visit 1948-08-31: periodic adult preventive visit. **S**
